Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  PCAS    PCA   FR0000053514

PCAS (PCA)

Delayed Quote. Delayed  - 09/23 02:21:33 pm
10.16 EUR   -2.59%
09/14 PCAS : ex-dividend day for interim dividend
09/07 PCAS : 1st half 2016 earnings report continued organic growth
09/02PCAS : half-yearly earnings release
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

PCAS : quarterly financial reporting Sep 30, 2011

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/07/2011 | 05:40pm CEST

Quarterly financial reporting
As of 30 September 2011

 

 

Business update

 

(in thousands of euros)20112010% change
 First Quarter44,05341,4346,3%
 including Pharmaceutical Synthesis27,14726,6032,0%
 including Specialty Chemicals16,90614,83114,0%
 Second Quarter41,78942,698-2,1%
 including Pharmaceutical Synthesis26,45728,100-5,8%
 including Specialty Chemicals15,33214,5985,0%
 Third Quarter33,48133,658-0,5%
 including Pharmaceutical Synthesis19,53018,3946,2%
 including Specialty Chemicals13,95115,264-8,6%
 Total as of 30 September119,323117,7901,3%
 including Pharmaceutical Synthesis73,13473,0970,1%
 including Specialty Chemicals46,18944,6933,3%

 

 

 

The PCAS Group's consolidated revenues at 30 September 2011came in 1.3% higher than the same period the previous year.

 

Pharmaceutical Synthesis
Over the first five months of the year, business was affected by the planned reduction in the contribution by the new contract between PCAS and Sanofi, effective since 31 May 2010. Excluding this contract, the Exclusive and Non-Exclusive Pharma business is up 10.5% at 30 September 2011.
Fine Specialty Chemicals
With growth of 3.3% at 30 September 2011, the Fine Specialty Chemicals business contracted by 8.6% during the third quarter of 2011 in relation to 2010, reflecting the economic slowdown seen since the summer.

 

Key operations and events for the quarter

 

No important events likely to have a significant impact on the company's business or situation occurred during the third quarter of 2011.

 

Outlook for the current year

 

The high level of sales expected for the fourth quarter should lead to earnings growth in 2011.

 

 

Next date :  2011 earnings, February 22nd, 2012

 

 

About PCAS
PCAS is a fine and specialty chemicals group that shares an ambition for excellence with its customers, which primarily include market-leading international groups. PCAS designs and delivers the best industrial solutions for its customers' specific expectations. These various expectations all share a common demand for safety, quality, competitiveness, innovation and sustainability.

 

Longjumeau, October 7th, 2011

 

PCAS_T3_2011_EN:
http://hugin.info/143512/R/1553112/478624.pdf



This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: PCAS via Thomson Reuters ONE

HUG#1553112
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PCAS
09/14 PCAS : ex-dividend day for interim dividend
09/07 PCAS : 1st half 2016 earnings report continued organic growth
09/02PCAS : half-yearly earnings release
07/19 PCAS : Net sales for the 1st half of 2016
07/19 PCAS : SUSTAINED GROWTH IN NET SALES FOR THE 1st HALF OF 2016
07/13 PCAS : signs a global distribution agreement with MilliporeSigma
07/13 PCAS : sign a global distribution agreement with MilliporeSigma
07/12 PCAS : Signs a global distribution agreement with MilliporeSigma, enabling a bet..
06/28 PCAS : Inauguration of a new workshop at the couterne site
06/28 PCAS : Inauguration of a new workshop at the couterne site
More news
Sector news : Pharmaceuticals - NEC
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira
09/23 Endo International CEO steps down, Campanelli named successor
09/23DJSHIRE : Files 8K - Direct Or Off-Balance Sheet Financial Obligation
More sector news : Pharmaceuticals - NEC
Advertisement
Financials (€)
Sales 2016 196 M
EBIT 2016 19,0 M
Net income 2016 11,0 M
Debt 2016 31,0 M
Yield 2016 1,18%
P/E ratio 2016 12,39
P/E ratio 2017 10,58
EV / Sales 2016 0,94x
EV / Sales 2017 0,88x
Capitalization 154 M
More Financials
Chart PCAS
Duration : Period :
PCAS Technical Analysis Chart | PCA | FR0000053514 | 4-Traders
Full-screen chart
Technical analysis trends PCAS
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Average target price 11,0 €
Spread / Average Target 8,3%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Vincent Touraille CEO & Financial Communications Contact
Christian Moretti Chairman
Pierre Schreiner Deputy Chief Executive Officer-Operations
Eric Moissenot Deputy CEO-Finance & Administration
Gérard Guillamot Director-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PCAS27.48%173
JOHNSON & JOHNSON15.66%325 050
ROCHE HOLDING LTD.-11.32%218 395
NOVARTIS AG-8.70%214 744
PFIZER INC.6.13%207 809
MERCK & CO., INC.19.20%174 098
More Results